鼻腔鼻窦NK/T细胞淋巴瘤的诊治与预后分析  

An Analysis on Treatment Outcomes and Prognosis in Nasal Type NK/T Cell Lymphoma

作　　者：江超武[1] 纳玉萍[1] 郭敏[1] 王锦[1] 方文琦[1] 

机构地区：[1]昆明医科大学第一附属医院,云南昆明650032

出　　处：《肿瘤学杂志》2014年第3期216-220,共5页Journal of Chinese Oncology

摘　　要：[目的]探讨鼻腔鼻窦NK/T细胞淋巴瘤的临床特点、治疗方法、预后以及影响预后的相关因素。[方法]回顾分析34例鼻腔鼻窦NK/T细胞淋巴瘤的临床资料,采用KaplanMeier法及Cox回归模型进行生存分析。[结果]鼻腔鼻窦NK/T细胞淋巴瘤总5年生存率、3年生存率及1年生存率分别为5.9%,17.6%,70.6%,中位生存时间为20.0月;Ⅰ期患者1年生存率为100.0%,3年生存率为33.3%;Ⅱ期患者1年生存率为62.5%,3年生存率为31.2%;Ⅲ、Ⅳ期患者1年生存率为66.6%,3年生存率为0。单纯手术治疗者1年生存率为66.6%,3年生存率为16.6%;CHOP方案化疗或术后化疗者1年生存率为50.0%,3年生存率为0;综合放化疗者1年生存率为100.0%,3年生存率为50.0%。有B症状者1年生存率为37.5%,3年生存率为25.0%;而无B症状患者1年生存率为69.1%,3年生存率为19.1%。[结论]鼻腔鼻窦NK/T细胞淋巴瘤预后差,肿瘤的分期、治疗的方式与预后有关,综合放化疗患者疗效明显好于其它治疗方案,放疗是早期NK/T细胞淋巴瘤的主要治疗方法。[Purpose] To investigate the clinical characteristics,treatment methods,prognosis and prognostic factors of patients with nasal type NK/T cell lymphoma. [Methods] Clinical data of 34 cases with nasal type NK/T cell lymphoma was analyzed retrospectively,and the survival were analyzed by Kaplan-Meier method and Cox regression model. [Results] The 5-,3-,1-year overall survival（OS） rates were 5.9%,17.6%,70.6% respectively,with median survival20 months. The 1-year and 3-year OS rates were 100.0% and 33.3% in patients with stage Ⅰ;62.5% and 31.2% in stage Ⅱ;66.6% and 0 in stage Ⅲ and Ⅳ,respectively. The 1-year and 3-year OS rates were 66.6% and 16.6% in patients with surgery alone,50.0% and 0 in patients treated by CHOP chemotherapy or postoperative chemotherapy,100.0% and 50.0% in patients treated by comprehensive radiochemotherapy. The 1-year and 3-year OS rates were 37.5% and25.0% in patients with B symptom,69.1% and 19.1% in patients without B symptoms. [Conclusion] The patients with nasaltype NK/T cell lymphoma have poor prognosis,which is related with tumor staging,treatment methods. The patients with comprehensive radiochemotherapy have better prognosis than patients with other treatments. Radiotherapy is the main treatment method for early stage nasal type NK/T cell lymphoma.

关 键 词：淋巴瘤 NK T细胞 鼻型 药物疗法 放射疗法 预后 

分 类 号：R739.62[医药卫生—肿瘤]